Core Insights - Kintor Pharmaceutical (300858.SZ) provides R&D services to clients, and its animal bifidobacterium lactis strain ProSci-246 has been applied to the company's ready-to-eat probiotic products, which are now available for sale [1] Company Summary - Kintor Pharmaceutical has successfully integrated the ProSci-246 strain into its product line, indicating a step forward in its probiotic offerings [1] - The launch of these ready-to-eat probiotic products marks a significant milestone for the company, showcasing its capabilities in R&D and product development [1] Industry Context - The application of advanced probiotic strains like ProSci-246 reflects the growing trend in the health and wellness industry towards innovative and functional food products [1] - The market for ready-to-eat probiotic products is expanding, driven by increasing consumer awareness of gut health and the benefits of probiotics [1]
科拓生物(300858.SZ):动物双歧杆菌乳亚种ProSci-246菌株已应用至公司即食型益生菌产品中